浙江大洋生物科技集团股份有限公司 关于2025年股权激励计划内幕信息知情人 及激励对象买卖公司股票情况的自查报告

Core Viewpoint - The company has approved the 2025 equity incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and core team members for long-term development [1][17]. Group 1: Equity Incentive Plan - The company held its third board meeting and third supervisory board meeting on June 6, 2025, where the 2025 equity incentive plan draft was approved [1]. - The plan aims to establish a long-term incentive mechanism to motivate directors, senior management, and core employees [17]. - The plan was developed in accordance with relevant laws and regulations, ensuring compliance with the Company Law and Securities Law [17][19]. Group 2: Insider Information Management - The company implemented necessary confidentiality measures regarding the equity incentive plan and registered insiders [2][6]. - A self-inspection was conducted on the trading activities of insiders and incentive objects during the six months prior to the plan's disclosure [3][4]. - No insider trading or information leakage was found during the self-inspection period, confirming compliance with legal regulations [7][6]. Group 3: Shareholder Meeting - The first temporary shareholder meeting of 2025 was held on June 26, 2025, with a total of 126 shareholders participating, representing 26.0116% of the total shares [15]. - The meeting approved the equity incentive plan with 99.2302% of the votes in favor, indicating strong support from shareholders [17][20]. - The meeting also addressed the authorization of the board to manage the equity incentive plan, which received 99.2076% approval [22][24].